Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

NCT06810141 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT06810141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
Lead sponsor
ImmunityBio, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

nmibc